A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kim, Youngkyun ^a   Yi, Hyoju ^a   Jung, Hyerin ^a   Rim, Yeri Alice ^a   Park, Narae ^a   Kim, Juryun ^a   Jung, Seung Min ^a   Park, Sung Hwan ^a   Park, Young Woo ^b   Ju, Ji Hyeon ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 6 RECEPTOR; PEPTIDE LIBRARY; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; BONE DEVELOPMENT; BONE MARROW CELL; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PEPTIDE LIBRARY; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE MARROW CELLS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, INBRED DBA; OSTEOGENESIS; PEPTIDE LIBRARY; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SYNOVIOCYTES;

EID: 84957542150     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20150     Document Type: Article

References (49)

1. Colmegna, I., Ohata, B. R. & Menard, H. A. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 91, 607-620 (2012).
2. Buch, M. H. & Emery, P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 23, 245-251 (2011).
3. Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10, 301-316 (2010).
4. McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7, 429-442 (2007).
5. Taylor, P. C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 10, 308-315 (2010).
6. Varani, K. et al. P2X(1) and P2X(3) purinergic receptors differentially modulate the inflammatory response in human osteoarthritic synovial fibroblasts. Cell Physiol Biochem 25, 325-336 (2010).
7. Moreland, L. W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337, 141-147 (1997).
8. Moreland, L. W. et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130, 478-486 (1999).
9. Genovese, M. C. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46, 1443-1450 (2002).
10. Tamura, T. et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90, 11924-11928 (1993).
11. Madhok, R., Crilly, A., Watson, J. & Capell, H. A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52, 232-234 (1993).
12. Alves, J. D., Marinho, A. & Serra, M. J. Tocilizumab: is there life beyond anti-TNF blockade? Int J Clin Pract 65, 508-513 (2011).
13. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997 (2008).
14. Fleischmann, R. M. et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 40, 113-126 (2013).
15. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 50, 1761-1769 (2004).
16. Silman, A. J. Available therapeutic options following failure of a first anti-TNF agent. Nat Clin Pract Rheumatol 5, 115 (2009).
17. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4, 11-22 (2004).
18. Chames, P. & Baty, D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1, 539-547 (2009).
19. Linke, R., Klein, A. & Seimetz, D. Catumaxomab: clinical development and future directions. MAbs 2, 129-136 (2010).
20. Veri, M. C. et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum 62, 1933-1943 (2010).
21. Kanakaraj, P. et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 4, 600-613 (2012).
22. Qi, J. et al. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis. Int Immunopharmacol 14, 770-778 (2012).
23. Liu, M. et al. A novel bispecific antibody targeting tumor necrosis factor α and ED-B fibronectin effectively inhibits the progression of established collagen-induce arthritis. J Biotechnol 186, 1-12 (2014).
24. Cha, H. S. et al. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol 34, 16-19 (2007).
25. Haworth, C. et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21, 2575-2579 (1991).
26. Li, Y., Li, P., Lin, S. H., Zheng, Y. Q. & Zheng, X. X. Paeonol inhibited TNF-alpha-induced GM-CSF expression in fibroblast-like synoviocytes. Int J Clin Pharmacol Ther 52, 986-996 (2014).
27. Ryu, J. H. et al. Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum 63, 2732-2743 (2011).
28. Gallucci, R. M., Lee, E. G. & Tomasek, J. J. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 126, 561-568 (2006).
29. Axmann, R. et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60, 2747-2756 (2009).
30. Lipsky, P. E. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 8 (Suppl 2), S4 (2006).
31. Wang, Q. T. et al. Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells. Pharmacol Res 68, 38-45 (2013).
32. Yi, H. et al. A new strategy to deliver synthetic protein drugs: self-reproducible biologics using minicircles. Sci Rep 4, 5961 (2014).
33. Chen, Z. Y., He, C. Y., Ehrhardt, A. & Kay, M. A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8, 495-500 (2003).
34. Chen, Z. Y., He, C. Y. & Kay, M. A. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 16, 126-131 (2005).
35. Gracey Maniar, L. E. et al. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther 21, 131-138 (2012).
36. Kontermann, R. E. Dual targeting strategies with bispecific antibodies. MAbs 4, 182-197 (2012).
37. Byrne, H., Conroy, P. J., Whisstock, J. C. & O'Kennedy, R. J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 31, 621-632 (2013).
38. Holmes, D. Buy buy bispecific antibodies. Nat Rev Drug Discov 10, 798-800 (2011).
39. Nagorsen, D., Kufer, P., Baeuerle, P. A. & Bargou, R. Blinatumomab: a historical perspective. Pharmacol Ther 136, 334-342 (2012).
40. Moelants, E. A., Mortier, A., Van Damme, J. & Proost, P. Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol 91, 393-401 (2013).
41. Takeuchi, T. et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70, 1208-1215 (2011).
42. Edrees, A. F., Misra, S. N. & Abdou, N. I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNFalpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 23, 469-474 (2005).
43. Yamaguchi, N. et al. Synergistic effect on the attenuation of collagen induced arthritis in tumor necrosis factor receptor I (TNFRI) and interleukin 6 double knockout mice. J Rheumatol 30, 22-27 (2003).
44. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67, 1516-1523 (2008).
45. Karsdal, M. A. et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 42, 131-139 (2012).
46. + T cells in collageninduced arthritis. Immunol Lett 117, 16-25 (2008).
47. Hückel, M. et al. Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1). Arthritis Res Ther 8, R17 (2006).
48. Kay, M. A., He, C. Y. & Chen, Z. Y. A robust system for production of minicircle DNA vectors. Nat Biotechnol 28, 1287-1289 (2010).
49. Adamopoulos, I. E. et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 187, 951-959 (2011).